Platelet-Rich Plasma Injection Versus Hydrodissection in the Treatment of Carpal Tunnel Syndrome - Trial NCT06368505
Access comprehensive clinical trial information for NCT06368505 through Pure Global AI's free database. This phase not specified trial is sponsored by Osama Ahmed Elshafei and is currently Recruiting. The study focuses on Carpal Tunnel Syndrome. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Osama Ahmed Elshafei
Mansoura University
Timeline & Enrollment
N/A
Jan 16, 2024
Jul 16, 2024
Primary Outcome
Boston Carpal Tunnel Syndrome Questionnaire (BCTQ),The visual analog scale (VAS)
Summary
The goal of this clinical trial is to compare the efficacy of Ultrasound-Guided Platelet-Rich
 Plasma Injection versus Hydrodissection (using 2ml saline, 2ml dexamethasone and 1ml
 lidocaine) in the Treatment of Carpal Tunnel Syndrome. The main questions it aims to answer
 are:
 
 - Which modality is more effective in reducing symptoms and improving function in patients
 with Carpal tunnel syndrome
 
 - Asses safety profile of both methods
 
 Participants will:
 
 - Randomized to one of the two arms
 
 - Visit the clinic 1 and 3 months after intervention
 
 - Assessed for efficacy and safety of the intervention
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06368505
Non-Device Trial